COVID Clinical Trials

HYDROXYCHLOROQUINE and AZITHRO for COVID Patients

Contact Person: Sabiha Hussain

A Randomized Control Trial on COVID + patients looking at viral load at baseline and day 6 as well as other clinical secondary outcomes. Patients will be randomize to:

  • Hydroxchloroquine+ azithro
  • Hydroxychloroquine
  • Nothing until 6 days after symptom onset and then hydroxchloroquine.
HCQ-Trial-Eligibility-checklist-4-14-20Download

Phase 3 randomized, open-labeled, multi-center study to evaluate the safety and antiviral activity of Remdesivir (GS-5734) in participants with severe and moderate COVID-19. Patients must have a confirmed SARS-CoV-2 infection confirmed by PCR test <4 days, Crcl >50 ml/min and LFTs <5x UNL. There are other inclusion/exclusion criteria. Contact Pinki Bhatt, MD (RWJ-NB Site PI) or Fei Chan, RN (CRC research coordinator) for enrollment evaluation. CLICK HERE for more information about the study.

Loader Loading…
EAD Logo Taking too long?

Reload Reload document
| Open Open in new tab

Download [279.20 KB]

Here is a comparison of the 2 current ongoing clinical trials (4/27/20):

A team of Rutgers physicians, led by co-principal investigators Dr. Martin Blaser, Dr. Jeffrey Carson and Dr. Reynold Panettieri, is conducting a critical COVID-19 study involving the spread of the virus among front-line healthcare workers. As part of the study, 250 asymptomatic RWJUH-New Brunswick physicians and employees involved in direct patient care will be tested for COVID-19, and undergo bloodwork and swabs over the course of several months. CLICK HERE to learn more. CLICK HERE if you are interested in participating in this study.